Medication Sector in Qatar: Hand in Hand Facing the Blockade

INTELLECTUAL PROPERTY, TECHNOLOGY TRANSFER, AND LOCAL PRODUCTION TO INCREASE ACCESS TO MEDICINES

MARIOS I. KATSILOUDES, PhD;
PROFESSOR OF STRATEGY & ENTREPRENEURSHIP
DEPARTMENT OF MANAGEMENT & MARKETING
COLLEGE OF BUSINESS AND ECONOMICS
QATAR UNIVERSITY
Disclosure of Conflict of Interest

Presenting Authors Have No Relationships to Disclose
• Intellectual Property [IP] is all about the results of human creativity.

• IP’s subject matter is formed from new ideas generated by human beings.

• Their application to human needs can be of considerable benefit to mankind.
INTELLECTUAL PROPERTY (IP): THE CONCEPT cont.

- Protecting the development and application of new ideas assists in the realization of the benefits that derive from these ideas.

- INTELLECTUAL PROPERTY LAW IS THE MEANS USED TO PROVIDE THIS PROTECTION.

- So it is about the rules protecting COPYRIGHT, PATENTS, TRADEMARKS, INDUSTRIAL DESIGNS AND GEOGRAPHICAL INDICATIONS.
QATAR and IP

• The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) under the umbrella of the World Trade Organization (WTO)

• Is an international legal agreement between all the member nations of the WTO (Qatar has been a member of the WTO since Jan. 13, 1996). It sets down minimum standards for the regulation by national governments of many forms of IP as applied to nationals of other WTO member nations.

• Qatar is also member of the World Intellectual Property Organization (WIPO)
WIPO

• WIPO was established in 1967 and Qatar has been a member of WIPO since September 1976.

• WIPO was created to:

1. promote the protection of IP throughout the world by co-operation among States and, where appropriate, in collaboration with any other international organizations; and

2. to ensure administrative co-operation among the intellectual property Unions.
QATAR’S OTHER MEMBERSHIPS


• Of the Patent Cooperation Treaty (the PCT), since August 3, 2011
The Patent Cooperation Treaty (PCT) makes it possible to seek patent protection for an invention simultaneously in each of a large number of countries by filing an "international" patent application.

Such an application may be filed by anyone who is a national or resident of a PCT Contracting State. It may generally be filed with the national patent office of the Contracting State of which the applicant is a national or resident or, at the applicant's option, with the International Bureau of WIPO in Geneva.
1. Law No. 7 of 2002 on the Protection of Copyright and Neighbouring Rights.
2. Law No. 9 of 2002 on Trade Marks, Trade Data, Trade Names, Geographical Indications and Industrial Designs.
3. Law No. 5 of 2005 on the Protection of Trade Secrets.
5. Law No. 30 of 2006 concerning Patents.
6. Legislation concerning plant variety protection is still under consideration.
TT IN THE PHARMA INDUSTRY REFERS TO THE PROCESSES OF SUCCESSFUL PROGRESS OF DRUG DISCOVERY TO PRODUCT DEVELOPMENT, CLINICAL TRIALS AND ULTIMATELY FULL SCALE COMMERCIALIZATION
FACETS OF TECHNOLOGY TRANSFER IN THE PHARMA INDUSTRY

1. Government labs to private sector firms
2. Between private sector firms of the same country
3. Between private sector firms of different countries
4. From academia to private sector firms
5. Academia, Government and industry collaborations
TECHNOLOGY TRANSFER FROM VARIOUS SECTORS

IDEA

- Start-up Firms
- R & D Firms

Research

Development

Production

Manufacturing

Distribution

- Universities
- Research Institutes

MARKET (Commercialization)
• For TT to be successful there needs to be a supportive business and scientific environment in the recipient country, and that environment should include skilled workers, economic and political stability, supportive regulatory environment, market size and potential and a well developed national infrastructure of natural resources and transport.

• Transparent and efficient regulation – Pharmaceuticals are necessarily a high regulated industry, the regulatory function must be efficient and transparent for technology transfer to be economically viable.
THE EXAMPLE OF IRELAND

- Ireland is the 7th largest exporter of medicinal and pharmaceutical products in the world (2014).
- Ireland is now the largest net exporter of pharmaceuticals in the EU accounting for over 50% of all exports from the country. In 2014 the sector exported products to the value of €64 billion.
- Approximately 120 overseas companies have plants in Ireland.
- Ireland has 9 of the top 10 largest pharmaceutical companies in the world with operations throughout the country.
- The sector contributes more than €1 billion in corporation tax to the Irish Exchequer annually.
- The international research-based pharmaceutical industry has invested over €7 billion in the last ten years in Ireland.
INVESTMENT INCENTIVES

• Ireland’s intellectual property laws provide companies with generous incentives to innovate. In conjunction, the Irish tax system which offers a highly competitive corporate tax rate of 12.5% is a major incentive. No tax is paid on earnings from intellectual property where the underlying R&D work was carried out in Ireland.

• Ireland recently introduced a new R&D Tax Credit, designed to encourage companies to undertake new and/or additional R&D activity in Ireland. It covers wages, elated overheads, plant/machinery and buildings. Stamp duty on intellectual property rights has been abolished.
• 46% of pharma employees are third-level graduates.

• 30% year on year growth in employment since 2008.

• 25% of all PhD researchers in Irish industry are employed in the sector.

• In 2008, 2 out of every 5 pharmaceutical jobs created in Europe were in Ireland.
PHARMACEUTICALS IN NUMBERS

WORLD'S TOP PHARMA FIRMS (SALES 2012)

- Pfizer: $47.4bn
- Novartis: $45.4bn
- Merck: $41.1bn
- Sanofi: $38.3bn
- Roche: $37.5bn
- GSK: $33.1bn
- AstraZeneca: $27.1bn
- Johnson & Johnson: $23.5bn
- Abbott Laboratories: $23.1bn
- Eli Lilly & Co.: $18.5bn

IRISH EMPLOYEES DIRECT
124,500

IRISH EMPLOYEES INDIRECT
24,000

VALUE OF IRELAND'S PHARMACEUTICAL EXPORTS 2012
124,500
€55bn

9 OF THE WORLD'S TOP TEN PHARMA COMPANIES HAVE PLANTS IN IRELAND
AstraZeneca is the exception

8th LARGEST PRODUCER OF PHARMACEUTICALS IN THE WORLD

€8bn
Research funding committed by Irish Government

120 OVERSEAS DRUG COMPANIES HAVE PLANTS IN IRELAND
2 CLUSTERS: DUBLIN AND CORK
HOTSPOTS: SALLING, WATERFORD, MAYO

SOURCE: PHARMACEUTICAL INDUSTRY ASSOCIATION, ENGAGE, IRELAND

17
THANK YOU FOR YOUR ATTENTION !!!